Bluebird Bio (BLUE) Rises 11% Despite Missing Estimates
Bluebird Bio (BLUE) rose 11% for the day, despite posting a Q3 loss and missing revenue estimates. BLUE came out with a quarterly loss of $0.92 per share, while also missing revenue estimates.
A few of the main highlights from the press release are:
- The commercial launch of ZYNTEGLO is expected in Q4 ’22
- Chris Krawtschuk was appointed the CFO
- BLUE ended the quarter with $186M in cash and cash equivalents.
The Company has promising products in the pipeline, which the company highlighted, and can be found here.
About bluebird bio, Inc.
bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days.
With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward.
Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world—setting the standard for the industry. Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds.
bluebird bio, ZYNTEGLO and SKYSONA are registered trademarks of bluebird bio, Inc. All rights reserved.
